Astria Therapeutics

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Astria Therapeutics advances STAR-0215 for HAE treatment market growth

Astria Therapeutics is making strides in developing STAR-0215 as a promising HAE preventative treatment.
Financially stable with recent stock offering, the company is focused on patient-centric innovation.
Challenges in patient enrollment and injection site reactions are being addressed proactively.
Opportunities lie in expanding clinical trials, optimizing dosing strategies, and achieving market approval.

Astria Therapeutics reports strong Q3 performance and eyes global expansion

Astria Therapeutics showcased promising data for STAR-0215 and introduced STAR-310 as potential game-changers in the therapeutic landscape.
Financially, the company is well-positioned with substantial cash reserves and secured funding for future operations, indicating stability and growth potential.
While facing challenges in trial logistics and global expansion, Astria Therapeutics has opportunities to establish market leadership in HAE and atopic dermatitis treatments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information on STAR-0215 and its development in three posters at the 2023 European Academy of Allergy, Asthma, and Immunology Annual Meeting in Hamburg, Germany on June 9-11, 2023. Nikolaos Biris, Ph.D., Direc.

Astria Therapeutics to Present STAR-0215 at the 2023 European Academy of Allergy, Asthma, and Immunology Annual Meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We are excited to be administering STAR-0215 to patients in the Phase 1b/2 ALPHA-STAR clinical trial. We on track to share initial.

Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information on STAR-0215 and its development in two presentations at the 13th C1-Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary. Jou-Ku Chung, Vice President, Clinical Pharmacology and Trans.

Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema Workshop

Astria: Biotech To Watch With Proof Of Concept Established For HAE.

Astria: Biotech To Watch With Proof Of Concept Established For HAE

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, announced today that it has promoted Andrea Matthews to Chief Business Officer. Ms.

Astria Therapeutics Names Andrea Matthews Chief Business Officer

Astria Therapeutics, Inc. (NASDAQ:ATXS ) Q4 2022 Earnings Conference Call March 22, 2023 8:30 AM ET Company Participants Andrea Matthews - Senior Vice President, Corporate Affairs Jill Milne - Chief Executive Officer Andy Nichols - Chief Scientific Officer Andrew Komjathy - Chief Commercial Officer Chris Morabito - Chief Medical Officer Noah Clauser - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Oliver McCammon - LifeSci Capital, LLC Joe Pantginis - H.C. Wainwright Eun Yang - Jefferies Michael Higgins - Ladenburg Thalmann Operator Good morning and welcome to the Astria Therapeutics 2022 Q4 and Full Year Financial Results and Business Update Conference Call.

Astria Therapeutics, Inc. (ATXS) Q4 2022 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter/full year 2022 financial results before the Nasdaq Global Market open on Wednesday, March 22, 2023. Jill C. Milne, Ph.D.

Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming virtual Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13th at 1:20pm ET.

Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc.

Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will share new STAR-0215 data in two poster presentations at the upcoming American Academy of Allergy, Asthma, and Immunology Annual Meeting in San Antonio, Texas on February 26, 2023 at 9:45am CST. Chris Morabito, M.D.

Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced the initiation of the ALPHA-STAR Phase 1b/2 clinical trial of STAR-0215 in people living with HAE. Initial proof-of-concept results in HAE patients from single and multiple dose cohorts are expected in mid-2024.

Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE

The average of price targets set by Wall Street analysts indicates a potential upside of 70.1% in Astria Therapeutics, Inc. (ATXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Astria Therapeutics, Inc. (ATXS) Have the Potential to Rally 70% as Wall Street Analysts Expect?

If you are looking for stocks that are well positioned to maintain their recent uptrend, Astria Therapeutics, Inc. (ATXS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

What Makes Astria Therapeutics, Inc. (ATXS) a Good Fit for 'Trend Investing'

ATXS has broken out from a 37-week price reversal. Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body.

Astria Therapeutics: Tailwinds Building With Novel Treatment Paradigm

BOSTON--( BUSINESS WIRE )--Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced the closing of its previously announced underwritten offering of 10,445,050 shares of its common stock, including the full exercise of the underwriters' option to purchase 1,362,397 shares of common stock, at a price of $11.01 per share. The gross proceeds of the offering were approximately $115 million, before deducting underwriting discounts and commissions and other offering expenses. All shares in the offering were offered by the Company.

Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

BOSTON--( BUSINESS WIRE )--Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced the pricing of an underwritten offering of 9,082,653 shares of its common stock at a price of $11.01 per share. The gross proceeds of the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, the underwriters have a 30-day option to purchase up to an additional 1,362,397 shares of common stock at the public offering price less underwriting discounts and commissions.

Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

BOSTON--( BUSINESS WIRE )--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced positive preliminary results from the Phase 1a clinical trial of STAR-0215 in healthy subjects establishing early proof of concept of STAR-0215 as a potential long-acting preventative treatment for HAE. STAR-0215 was well-tolerated at all doses studied. The results showed rapid and sustained drug levels consistent with clinical benefit and sustained target engagement with plasma kallikrein inhibition for at least three months, supporting the potential for STAR-0215 to be dosed once every three months or less frequently. Astria plans to initiate the ALPHA-STAR Phase 1b/2 trial in HAE patients in Q1 2023.

Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects

BOSTON--( BUSINESS WIRE )--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that it will share preclinical data for STAR-0215 in a presentation titled “Modeling and Simulation Predicts Robust HAE Attack Suppression with Every Three Month Dosing of STAR-0215” at the 2022 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Louisville, Kentucky.

Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting

Akero Therapeutics Inc

HeartBeam

ContraFect

Humanigen

Otonomy

Rhythm Pharmaceuticals

Vigil Neuroscience

Virios Therapeutics

The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that the Company will host a virtual R&D Day titled “Update on STAR-0215 and Its Clinical Development for the Prevention of HAE Attacks” on September 30th from 10:30am to 12:00pm ET. The event will feature a presentation by Dr. Marc Ried

Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that the Company will be presenting at two upcoming investment conferences: H.C. Wainwright 24th Annual Global Investment Conference: Jill C. Milne, Ph.D., Chief Executive Officer at Astria will present a corporate overview and provide information

Astria Therapeutics to Present at Upcoming Investment Conferences

The mean of analysts' price targets for Astria Therapeutics, Inc. (ATXS) points to a 234.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Astria Therapeutics, Inc. (ATXS) Have the Potential to Rally 234% as Wall Street Analysts Expect?

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update. “We are thrilled to announce that we have initiated dosing in our Phase 1a trial of STAR-0215 which will provide data that we believe will validate

News for Astria Therapeutics Stock (ATXS)